Get the Stockscreener App
90.61
0.50%
0.45
After Hours:
89.38
-1.23
-1.36%
Spruce Biosciences Inc stock is traded at $90.61, with a volume of 45,765.
It is up +0.50% in the last 24 hours and down -13.66% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
See More
Previous Close:
$90.16
Open:
$89.7
24h Volume:
45,765
Relative Volume:
0.09
Market Cap:
$96.99M
Revenue:
$7.10M
Net Income/Loss:
$-39.43M
P/E Ratio:
-96.39
EPS:
-0.94
Net Cash Flow:
$-46.50M
1W Performance:
-17.63%
1M Performance:
-13.66%
6M Performance:
-86.69%
1Y Performance:
-90.34%
1-Day Range:
$83.00
$92.40
1-Week Range:
$74.01
$111.00
52-Week Range:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
90.61 | 96.50M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-28-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
Leerink Partners Upgrades Spruce Biosciences (SPRB) - Nasdaq
Spruce Biosciences Shares Rise After Upgrade From Leerink - MarketScreener
SPRB: Leerink Partners Upgrades to Outperform with $160 Target | - GuruFocus
Leerink Partners upgrades Spruce Biosciences stock to Outperform By Investing.com - Investing.com Canada
Leerink Partners upgrades Spruce Biosciences stock to Outperform - Investing.com
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
Spruce Biosciences (SPRB) Price Target Increased by 2,045.14% to 137.19 - Nasdaq
Citizens raises Spruce Biosciences stock price target to $259 on MPS IIIB therapy - Investing.com Australia
Citizens raises Spruce Biosciences stock price target to $259 on MPS IIIB therapy By Investing.com - Investing.com South Africa
Citizens Maintains Spruce Biosciences (SPRB) Market Outperform Recommendation - Nasdaq
SPRB: Citizens Raises Price Target for Spruce Biosciences | SPRB Stock News - GuruFocus
Spruce Biosciences Reports Q3 2025 Financial Results - TipRanks
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - BioSpace
SPRB Announces Key Financing Milestones and Regulatory Achieveme - GuruFocus
Spruce Biosciences Q3 net loss narrows - MarketScreener
Spruce Biosciences Inc expected to post a loss of $13.93 a shareEarnings Preview - TradingView
Spruce Biosciences (SPRB) Expected to Announce Earnings on Monday - MarketBeat
One new option listing and two option delistings on September 5th - MSN
Small Cap Stocks To Follow TodayOctober 6th - MarketBeat
Biotech And Tech Stocks Rally On Breakthrough News And Partnerships - Finimize
Spruce Biosciences (SPRB) Price Target Decreased by 37.30% to 6.40 - MSN
[S-3] SPRUCE BIOSCIENCES, INC. Shelf Registration Statement | SPRB SEC FilingForm S-3 - Stock Titan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by Brokerages - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Outperform" at Citizens Jmp - MarketBeat
Spruce Biosciences Stock Rallied 1184%Have You Assessed the Risk - Trefis
JMP Securities Upgrades Spruce Biosciences (SPRB) - Nasdaq
Cash per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView
SPRB: JMP Securities Upgrades Spruce Biosciences to Market Outpe - GuruFocus
Spruce Biosciences Raised to Market Outperform From Market Perform by JMP Securities - 富途牛牛
Spruce Biosciences stock upgraded by Citizens on promising MPS IIIB therapy - Investing.com Nigeria
Spruce Biosciences Stock Dropped 16%Have You Assessed the Risk - Trefis
Spruce Biosciences (NASDAQ:SPRB) Stock Rating Lowered by Zacks Research - MarketBeat
What is Leerink Partnrs' Forecast for SPRB FY2025 Earnings? - MarketBeat
Levi & Korsinsky Reminds Spruce Biosciences Investors of the Ongoing Investigation into Potential Violations of Securities LawsSPRB - ACCESS Newswire
Spruce Biosciences Announces $50 Million Private Placement Financing - Global Legal Chronicle
Spruce Biosciences CFO vests 2,053 RSUs; owns 6,066 shares - Stock Titan
SPRB insider filing: CEO nets 3,245 shares after RSU vest - Stock Titan
The science behind the therapy that catapulted a biopharma’s stock 1,400% and counting - Healthcare Brew
Leerink Partners Maintains Spruce Biosciences (SPRB) Market Perform Recommendation - Nasdaq
Spruce Biosciences (SPRB): Analyst Raises Price Target Significa - GuruFocus
Spruce Biosciences stock price target raised to $160 from $10 at Leerink - Investing.com Philippines
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025) - ts2.tech
Mintz Advises the Placement Agents in Spruce Biosciences, Inc.’s $50 Million Private Placement - Mintz
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough News – Experts Weigh In - ts2.tech
Spruce Biosciences (NASDAQ:SPRB) Upgraded at Zacks Research - Defense World
SPRUCE BIOSCIENCES, INC. trading resumes - MSN
Spruce Biosciences (NASDAQ:SPRB) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
SPRB director steps down; company notes no disagreement - Stock Titan
Spruce Biosciences, Inc. Announces Resignation of Bali Muralidhar as Member of Board of Directors and as Member of the Compensation Committee of the Board, Effective October 15, 2025 - MarketScreener
Spruce Biosciences Stock More Than Quadruples After Breakthrough Therapy Designation To Therapy For Rare And Fatal Genetic Disease - MSN
Head to Head Contrast: PyroGenesis Canada (NASDAQ:PYRGF) vs. Spruce Biosciences (NASDAQ:SPRB) - Defense World
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):